Prevalence, Risk Factors and Consequences Related to Cesarean Scar Defect (Defect in Cesarean Scar)

NCT02717312 | Completed

• 1 other identifier: R15104
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

The rates of cesarean section (CS) are rising all over the world. Worldwide the number of CS is millions every year. CS is one of the most frequently performed operation for women. As a consequence many women have a scar in their uterus. Cesarean scar may be associated with complications in later pregnancies. In recent years there have also been a few reports indicating that cesarean scar could potentially be associated with menstrual disorders and infertility. The impact of cesarean scar defect on long term welfare or quality of life is not clear. In some women with a history of CS it is possible to recognise a defect in the site of previous uterotomy years after the performed CS by sonographic examination. This defect in the scar, also called as a niche, is a consequence of incomplete healing of the scar in the lower part of uterus. To date there is uncertainty relating to the factors that lead to poor healing of cesarean scar. Also impact of cesarean scar defect on later well-being and later pregnancies are not properly known. The purpose of this study is to investigate the prevalence and the risk factors of cesarean scar defect. Also the impact of cesarean scar defect on women´s menstrual health, fertility, further deliveries and quality of life will be investigated. This study is a prospective observational cohort study. Women at the age of 18-45 years who will give birth by elective or emergency CS will be asked to participate. Women are recruited within two days of CS. Women with known uterus anomaly or von Willebrand disease will be excluded. The prevalence of scar defect will be evaluated by transvaginal sonography and contrast-enhanced sonohysterography using saline infusion. Both 2-dimensional and 3-dimensional sonography will be used. Sonographic evaluation will take place 6 months after the CS. The following definition for CS scar defect will be used: myometrial discontinuity with a depth of ≥2 mm at the site of cesarean scar that communicates with the uterine or cervical cavity as seen on transvaginal sonography with or without saline infusion. The prevalence of menstrual disorders will be evaluated 12 months after the CS. The subjects will be asked to report the number of menstrual bleeding days once a month during 3 consecutive months. Postmenstrual spotting is defined as ≥2 days of brownish discharge at the end of menstruation with total bleeding days of ≥7 or non-cyclic bleeding not related to menstruation.

Conditions

Cesarean Scar Defect

Outcome Measures

Primary Outcomes (1)

• Association between cesarean scar defect and post menstrual spotting

  Postmenstrual spotting is defined as ≥2 days of brownish discharge at the end of menstrual bleeding with total bleeding days ≥7 or inter menstrual non-cyclic bleeding not related to menstruation.

  15 months

Secondary Outcomes (4)

• Quality of life related to cesarean scar defect

  10 years

• Association between cesarean scar and adverse pregnancy outcome

  10 years

• Prevalence of cesarean scar defect measured by sonography

  6 months

• Impact of cervical opening at the time of cesarean section on the prevalence of cesarean scar defect.

  6 months

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Pregnant women undergoing cesarean section

You may qualify if:

• Women who gives birth by cesarean section whether it will be an elective surgery or an emergency surgery during labour

You may not qualify if:

• Uterus anomaly or von Willebrand disease
• Informed consent not provided

Sponsors & Collaborators

• Tampere University Hospital: lead
• City of Tampere: collaborator
• Finnish Medical Foundation: collaborator
• Competitive State Research Funding of Tampere University Hospital: collaborator
• Tampere University Hospital Support Foundation: collaborator

Study Sites (1)

Tampere University Hospital

Tampere, 33521, Finland

Location

Study Officials

• Synnöve Staff, MC PhD

  Tampere University Hospital

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 9, 2016
• First Posted: March 23, 2016
• Study Start: January 1, 2016
• Primary Completion: September 1, 2017
• Study Completion: May 1, 2021
• Last Updated: September 29, 2021

Record last verified: 2021-09

Data Sharing

• IPD Sharing: Will not share

Locations

FI (1)